Drug Profile
Atuveciclib - Bayer
Alternative Names: BAY1143572Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Bayer
- Class Antineoplastics; Small molecules; Triazines
- Mechanism of Action Cyclin dependent kinase 9 inhibitors; Positive transcriptional elongation factor B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Leukaemia
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Second-line therapy or greater) in USA (PO)
- 28 Mar 2018 No recent reports of development identified for phase-I development in Leukaemia(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (PO)
- 28 Mar 2018 No recent reports of development identified for phase-I development in Leukaemia(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)